Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency (Q45887249)

17 December 2017

title

Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency (English)

1 reference

17 December 2017

main subject

angiogenesis inhibitor

1 reference

W Wang

1

1 reference

17 December 2017

Y Ma

2

1 reference

17 December 2017

J Li

3

1 reference

17 December 2017

H-S Shi

4

1 reference

17 December 2017

L-Q Wang

5

1 reference

17 December 2017

F-C Guo

6

1 reference

17 December 2017

J Zhang

7

1 reference

17 December 2017

D Li

8

1 reference

17 December 2017

B-H Mo

9

1 reference

17 December 2017

F Wen

10

1 reference

17 December 2017

T Liu

11

1 reference

17 December 2017

Y-T Liu

12

1 reference

17 December 2017

Y-S Wang

13

1 reference

17 December 2017

Y-Q Wei

14

1 reference

17 December 2017

publication date

2 May 2013

1 reference

17 December 2017

published in

Gene Therapy

1 reference

17 December 2017

volume

20

1 reference

17 December 2017

issue

10

1 reference

17 December 2017

page(s)

970-978

1 reference

17 December 2017

https://scigraph.springernature.com/pub.10.1038/gt.2013.19

exact match

0 references

cites work

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

The promise and potential pitfalls of chimeric antigen receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Rejection of Syngeneic Colon Carcinoma by CTLs Expressing Single-Chain Antibody Receptors Codelivering CD28 Costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Immature B cell malignancies synthesize VEGF, VEGFR-1 (Flt-1) and VEGFR-2 (KDR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Vascular endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of IMC-18F1 (Human antibody targeting vascular endothelial growth factor receptor-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

New non-viral method for gene transfer into primary cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Nucleofection as an efficient nonviral transfection method for human monocytic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

IL-15/IL-15 receptor biology: a guided tour through an expanding universe

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Cytokine control of memory T-cell development and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Anti-VEGF/VEGFR therapy for cancer: reassessing the target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Molecular mechanisms of resistance to tumour anti-angiogenic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Pathways mediating resistance to vascular endothelial growth factor-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

7 January 2021

MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

7 January 2021

Transplacental carcinogenesis by stilbestrol

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

7 January 2021

Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activation

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

7 January 2021

Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.19

7 January 2021

Identifiers

DOI

10.1038/GT.2013.19

1 reference

17 December 2017

Dimensions Publication ID

0 references

1 reference

17 December 2017